Hospital de Sant Pau

Cost-Effectiveness of a Host-Response Point-of-Care Assay for Early Sepsis Diagnosis in UK Emergency Departments

BACKGROUND: Early recognition of sepsis in emergency departments (EDs) improves outcomes and reduces healthcare resource use. However, current clinical practice (CCP), largely based on the National Early Warning Score 2 (NEWS2) and clinical judgement, has limited diagnostic sensi...

Elucidating the mechanism underlying incomplete immune recovery in people living with HIV through CD4⁺ and CD8⁺ T cell multi-omics

A subset of people living with HIV (PLHIV), known as immunological non-responders (INR), fails to achieve adequate CD4⁺ T cell recovery despite viral suppression with antiretroviral therapy (ART). These individuals face an increased risk of adverse clinical outcomes. This study a...

Smoking cessation experiences during alcohol and cannabis treatment in substance use programmes in Catalonia: A qualitative study

Tobacco use remains disproportionately high among people receiving treatment for alcohol or cannabis use, yet it is rarely addressed in substance use services. This study explored the lived experiences of people who smoke while undergoing treatment for alcohol and/or cannabis use...

Genetic Testing After Heart Transplantation Uncovers Heritable Disease and Drives Family Screening

BACKGROUND: Genetic testing (GT) is established in ambulatory cardiomyopathy (CM), but its utility after heart transplantation (HTx) recipients remains poorly characterized. OBJECTIVES: This study aimed to evaluate the clinical utility of GT in adult HTx recipients with CM, focus...

Treatment-free remission after bosutinib discontinuation (BOSUTFR): results from a multicenter real-world study by the Spanish CML group

Treatment-free remission (TFR) is an established therapeutic goal for patients with chronic myeloid leukemia (CML) achieving sustained deep molecular response (DMR) on tyrosine kinase inhibitors (TKIs). However, evidence on TFR following bosutinib discontinuation remains limited....